EE200300559A - Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks - Google Patents

Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks

Info

Publication number
EE200300559A
EE200300559A EEP200300559A EEP200300559A EE200300559A EE 200300559 A EE200300559 A EE 200300559A EE P200300559 A EEP200300559 A EE P200300559A EE P200300559 A EEP200300559 A EE P200300559A EE 200300559 A EE200300559 A EE 200300559A
Authority
EE
Estonia
Prior art keywords
osteopontin
prevention
treatment
neurological disorders
agonist
Prior art date
Application number
EEP200300559A
Other languages
English (en)
Inventor
Boschert Ursula
Feger Georg
Selvaraju Raghuram
Papoian Ruben
Bernasconi Lilia
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200300559A publication Critical patent/EE200300559A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
EEP200300559A 2001-05-17 2002-05-08 Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks EE200300559A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111296 2001-05-17
PCT/EP2002/005081 WO2002092122A2 (en) 2001-05-17 2002-05-08 Use of osteopontin for the treatment and/or prevention of neurologic diseases

Publications (1)

Publication Number Publication Date
EE200300559A true EE200300559A (et) 2004-02-16

Family

ID=8177366

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300559A EE200300559A (et) 2001-05-17 2002-05-08 Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks

Country Status (26)

Country Link
US (4) US7217687B2 (et)
EP (1) EP1389130B1 (et)
JP (2) JP4417632B2 (et)
KR (1) KR100947424B1 (et)
CN (2) CN1939538A (et)
AT (1) ATE555803T1 (et)
AU (1) AU2002312886B2 (et)
BG (1) BG108337A (et)
BR (1) BR0209812A (et)
CA (1) CA2443964A1 (et)
CZ (1) CZ20033109A3 (et)
EA (1) EA006655B1 (et)
EE (1) EE200300559A (et)
ES (1) ES2387082T3 (et)
HR (1) HRP20030840A2 (et)
HU (1) HUP0400005A3 (et)
IL (2) IL158867A0 (et)
MX (1) MXPA03010327A (et)
NO (1) NO20035025D0 (et)
NZ (1) NZ528852A (et)
PL (1) PL211763B1 (et)
SK (1) SK14232003A3 (et)
UA (1) UA85368C2 (et)
WO (1) WO2002092122A2 (et)
YU (1) YU89503A (et)
ZA (1) ZA200307956B (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389306A2 (de) * 2001-05-09 2004-02-18 BioVisioN AG Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
AU2002357748A1 (en) * 2001-11-21 2003-06-10 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
EP1517695A4 (en) * 2002-06-25 2010-09-01 Aventis Pharma Inc OSTEOPONTIN, OLIGODENDROCYTES AND MYELINATION
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
CN1791422A (zh) * 2003-03-28 2006-06-21 应用研究系统Ars股份公司 凝聚素在治疗和/或预防周围神经疾病中的用途
MXPA06003117A (es) * 2003-09-18 2009-09-04 Arla Foods Amba Formula infantil.
EP1684797A1 (en) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
WO2006087579A1 (en) * 2005-02-18 2006-08-24 Proximagen Ltd. Treatment for neurodegeneration
US20060264371A1 (en) * 2005-02-18 2006-11-23 Proximagen Ltd. Treatment
AU2006304274B2 (en) 2005-10-13 2012-08-16 Celularity Inc. Production of oligodendrocytes from placenta-derived stem cells
EP1870107A1 (en) * 2006-06-23 2007-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
WO2008086449A2 (en) * 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
US20100069254A1 (en) * 2008-09-16 2010-03-18 Laree Hiser Cell Culture Model for Demyelination/Remyelination
KR101449100B1 (ko) * 2011-04-21 2014-10-13 가톨릭대학교 산학협력단 신경세포 데브리스 제거용 오스테오폰틴
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
WO2014051398A1 (ko) * 2012-09-28 2014-04-03 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
AU2015308899B2 (en) * 2014-08-27 2020-05-28 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
EP3458036B1 (en) * 2016-05-20 2023-08-23 Cedars-Sinai Medical Center Treating or preventing alzheimer's disease and associated conditions
US10954280B2 (en) * 2016-11-27 2021-03-23 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from micro algae
CN110545834B (zh) 2017-05-04 2024-02-20 富力卡姆股份公司 用于治疗糖尿病的肽
US11484576B2 (en) * 2017-08-15 2022-11-01 The Children's Medical Center Corporation Methods of promoting corticospinal neuronal outgrowth in neuronal lesions using a pro-regenerative human osteopontin fragment
WO2019226643A1 (en) * 2018-05-25 2019-11-28 The Children's Medical Center Corporation Methods for treating spinal cord injury
TR201903865A2 (tr) * 2019-03-14 2020-09-21 Bogazici Ueniversitesi Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi
WO2021024265A1 (en) * 2019-08-08 2021-02-11 Ramot At Tel-Aviv University Ltd. Methods of treating non-infectious inflammatory disorders
CN111388654A (zh) * 2020-05-22 2020-07-10 南通大学 治疗脊髓损伤的药物、药物试剂盒及方法
US20230265435A1 (en) * 2020-06-02 2023-08-24 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition comprising osteopontin inhibitor as active ingredient for prevention, alleviation, or treatment of neurodegenerative disease
CN117720620B (zh) * 2023-12-13 2024-07-23 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
IL145891A0 (en) 1999-04-15 2002-07-25 Childrens Medical Center Methods and compositions for modulating an immune response
WO2000064460A2 (en) * 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
MXPA02003176A (es) 1999-10-04 2002-09-30 Shearwater Corp Neuropeptidos estabilizados por polimero.

Also Published As

Publication number Publication date
ZA200307956B (en) 2004-10-13
EP1389130B1 (en) 2012-05-02
AU2002312886B2 (en) 2007-10-25
JP4417632B2 (ja) 2010-02-17
HK1067051A1 (en) 2005-04-01
YU89503A (sh) 2006-05-25
IL158867A0 (en) 2004-05-12
IL158867A (en) 2010-05-17
WO2002092122A2 (en) 2002-11-21
ATE555803T1 (de) 2012-05-15
US20080213234A1 (en) 2008-09-04
HUP0400005A3 (en) 2012-09-28
ES2387082T3 (es) 2012-09-13
NZ528852A (en) 2005-12-23
US20070225214A1 (en) 2007-09-27
BG108337A (bg) 2004-12-30
KR100947424B1 (ko) 2010-03-12
UA85368C2 (ru) 2009-01-26
US20040235720A1 (en) 2004-11-25
MXPA03010327A (es) 2004-02-17
KR20040008176A (ko) 2004-01-28
CZ20033109A3 (en) 2004-06-16
CN1533283A (zh) 2004-09-29
JP2004536058A (ja) 2004-12-02
PL367065A1 (en) 2005-02-21
SK14232003A3 (sk) 2004-05-04
JP2009191082A (ja) 2009-08-27
US20050176639A1 (en) 2005-08-11
BR0209812A (pt) 2004-06-01
WO2002092122A3 (en) 2003-03-06
PL211763B1 (pl) 2012-06-29
NO20035025L (no) 2003-11-12
CN1939538A (zh) 2007-04-04
EA200301253A1 (ru) 2004-06-24
CA2443964A1 (en) 2002-11-21
NO20035025D0 (no) 2003-11-12
EP1389130A2 (en) 2004-02-18
HUP0400005A2 (hu) 2004-04-28
US7217687B2 (en) 2007-05-15
JP5036761B2 (ja) 2012-09-26
HRP20030840A2 (en) 2005-08-31
CN1286524C (zh) 2006-11-29
EA006655B1 (ru) 2006-02-24
US7297099B2 (en) 2007-11-20

Similar Documents

Publication Publication Date Title
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
NO20034056D0 (no) Proliferative sykdommer
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
MY124786A (en) Bis-arylsulfones
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
MXPA05010414A (es) Uso de clusterina para el tratamiento y/o prevencion de enfermedades neurologicas perifericas.
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
UA85187C2 (en) 2-aminobenzoyl derivatives
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
EE200200670A (et) S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name